Replies to post #222999 on Biotech Values

[dewophile]

ESPR
I am more bullish on the prospects for the drug than you are despite the recent pricing adjustments for PCSK9 inhibitors. There is a mental hurdle for many patients to go on an injectable and I really think a PO drug will get used before moving to injectable a lot of the time
A lot of course is tied to the MACE trial